Higher rate of endophthalmitis after 25-gauge PPV

Article

The rate of endophthalmitis after 25-gauge pars plana vitrectomy (PPV) is significantly higher than that after 20-gauge PPV.

The rate of endophthalmitis after 25-gauge pars plana vitrectomy (PPV) is significantly higher than that after 20-gauge PPV, according to the results of a study published in the January issue of Retina.

Ingrid Scott from the Bascom Palmer Eye Institute, Miami, USA and colleagues from other US ophthalmic centers conducted a computerized database search at each centre to identify all patients who had undergone PPV between January 1, 2005 and December 31, 2006, and who were subsequently treated for endophthalmitis. In addition, all patients who underwent PPV and were subsequently treated for endophthalmitis at Pennsylvania State College of Medicine and Bascom Palmer Eye Institute during the study period were included. The medical records of these patients were reviewed to confirm that the endophthalmitis was associated with PPV.

The incidence of endophthalmitis during the study period was two cases per 6,375 patients (0.03%) for 20-gauge PPV compared with 11 cases per 1,307 patients (0.84%) for 25-gauge PPV (p<0.0001). Of 11 eyes that developed endophthalmitis after 25-gauge PPV, nine received endophthalmitis prophylaxis with subconjunctival cefazolin after surgery. Cultures were negative in three cases and no culture specimens were obtained in one case. Six of the seven isolates were coagulase-negative staphylococci, and one was enterococcus. Five of six isolates tested for sensitivity to vancomycin were sensitive, and both isolates tested for sensitivity to ceftazidime were sensitive.

In addition to discovering that the rate of endophthalmitis after 25-gauge PPV is significantly higher than that after 20-gauge PPV, endophthalmitis after 25-gauge was usually due to coagulase-negative staphylococci sensitive to vancomycin, and was associated with variable visual outcomes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.